Atea announced that its Board has authorized, and will promptly begin executing upon, the repurchase of up to $25M of the Company’s common stock. This authorization reflects the Company’s commitment to return capital to shareholders, while maintaining the flexibility needed to continue funding its global Phase 3 HCV program and positioning Atea for long-term success.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVIR:
- Atea Pharmaceuticals appoints Howard Berman to board of directors
- Atea Pharmaceuticals price target lowered to $6 from $6.20 at Morgan Stanley
- Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study
- Atea Pharmaceuticals cuts 25% of workforce, exploring partnerships
- Radoff-JEC Group nominates candidates to Atea Pharmaceuticals board